Despite High Asthma Biologics Response Rate, Severe Disease Control Is Lacking
Asthma biologic response is high in patients with severe asthma, yet few of these patients have their severe disease under control.
Stay updated with breaking news from Asthma Quality. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Asthma biologic response is high in patients with severe asthma, yet few of these patients have their severe disease under control.
Higher baseline blood eosinophil count was linked to improvement in asthma exacerbations and overall better outcomes seen with biologic therapies.
WASHINGTON — Male and female patients experienced similar improvements in their severe, uncontrolled asthma with tezepelumab over a 52-week period, according to data presented at the American Thoracic Society International Conference.“Sex-related differences in asthma prevalence and severity are well documented,” Monica Kraft, MD, Murray M. Rosenberg Professor of Medicine and
Adults with severe asthma showed similar improvements in symptoms and quality of life after treatment with BT as compared with biologics.
An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.